PeptiCHIP: A Microfluidic Platform for Tumor Antigen Landscape Identification.

Publisher: American Chemical Society Country of Publication: United States NLM ID: 101313589 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1936-086X (Electronic) Linking ISSN: 19360851 NLM ISO Abbreviation: ACS Nano Subsets: MEDLINE

Original Publication: Washington D.C. : American Chemical Society

Histocompatibility Antigens Class I* ; Microfluidics*; Antigens, Neoplasm ; Humans ; Ligands ; Peptides

Identification of HLA class I ligands from the tumor surface (ligandome or immunopeptidome) is essential for designing T-cell mediated cancer therapeutic approaches. However, the sensitivity of the process for isolating MHC-I restricted tumor-specific peptides has been the major limiting factor for reliable tumor antigen characterization, making clear the need for technical improvement. Here, we describe our work from the fabrication and development of a microfluidic-based chip (PeptiCHIP) and its use to identify and characterize tumor-specific ligands on clinically relevant human samples. Specifically, we assessed the potential of immobilizing a pan-HLA antibody on solid surfaces via well-characterized streptavidin-biotin chemistry, overcoming the limitations of the cross-linking chemistry used to prepare the affinity matrix with the desired antibodies in the immunopeptidomics workflow. Furthermore, to address the restrictions related to the handling and the limited availability of tumor samples, we further developed the concept toward the implementation of a microfluidic through-flow system. Thus, the biotinylated pan-HLA antibody was immobilized on streptavidin-functionalized surfaces, and immune-affinity purification (IP) was carried out on customized microfluidic pillar arrays made of thiol-ene polymer. Compared to the standard methods reported in the field, our methodology reduces the amount of antibody and the time required for peptide isolation. In this work, we carefully examined the specificity and robustness of our customized technology for immunopeptidomics workflows. We tested this platform by immunopurifying HLA-I complexes from 1 × 10 ⁶ cells both in a widely studied B-cell line and in patients-derived ex vivo cell cultures, instead of 5 × 10 ⁸ cells as required in the current technology. After the final elution in mild acid, HLA-I-presented peptides were identified by tandem mass spectrometry and further investigated by in vitro methods. These results highlight the potential to exploit microfluidics-based strategies in immunopeptidomics platforms and in personalized immunopeptidome analysis from cells isolated from individual tumor biopsies to design tailored cancer therapeutic vaccines. Moreover, the possibility to integrate multiple identical units on a single chip further improves the throughput and multiplexing of these assays with a view to clinical needs.

J Clin Invest. 2015 Sep;125(9):3401-12. (PMID: 26214521)
Cell. 2018 Apr 5;173(2):515-528.e17. (PMID: 29625057)
Immunology. 2018 Jul;154(3):331-345. (PMID: 29658117)
Eur J Cancer. 2017 Aug;81:116-129. (PMID: 28623775)
J Proteomics. 2014 Sep 23;109:240-4. (PMID: 25050860)
Bioinformatics. 2016 Sep 15;32(18):2847-9. (PMID: 27207943)
Mol Cell Proteomics. 2015 Dec;14(12):3105-17. (PMID: 26628741)
Methods Mol Biol. 2018;1719:209-221. (PMID: 29476514)
Adv Biosyst. 2019 Jan;3(1):e1800245. (PMID: 32627340)
Immunity. 2017 Aug 15;47(2):203-208. (PMID: 28813649)
J Immunother Cancer. 2019 Nov 18;7(1):309. (PMID: 31735170)
J Clin Invest. 2016 Dec 1;126(12):4690-4701. (PMID: 27841757)
Immunogenetics. 2009 Jan;61(1):1-13. (PMID: 19002680)
Science. 2015 Jan 23;347(6220):1260419. (PMID: 25613900)
Front Oncol. 2019 Nov 20;9:1270. (PMID: 31824850)
Leukemia. 2016 Apr;30(4):1003-4. (PMID: 27049048)
Mol Cell Proteomics. 2018 Mar;17(3):533-548. (PMID: 29242379)
Int J Mol Sci. 2018 Dec 07;19(12):. (PMID: 30544541)
Front Immunol. 2018 Jul 25;9:1716. (PMID: 30090105)
Cancer Immunol Immunother. 2004 Mar;53(3):187-95. (PMID: 14758508)
PLoS Comput Biol. 2012;8(5):e1002517. (PMID: 22615552)
Oncotarget. 2015 Aug 7;6(22):19290-304. (PMID: 26079540)
OMICS. 2012 May;16(5):284-7. (PMID: 22455463)
Blood. 2012 Jun 28;119(26):e181-91. (PMID: 22438248)
Hum Immunol. 2003 Jan;64(1):44-55. (PMID: 12507814)
Science. 2020 Aug 21;369(6506):936-942. (PMID: 32820119)
Nat Protoc. 2019 Jun;14(6):1687-1707. (PMID: 31092913)
Front Med (Lausanne). 2015 Sep 25;2:68. (PMID: 26442270)
Proc Natl Acad Sci U S A. 2010 Nov 2;107(44):18769-76. (PMID: 20974924)
Front Immunol. 2019 May 22;10:999. (PMID: 31178856)
Brain. 2012 Apr;135(Pt 4):1042-54. (PMID: 22418738)
Nat Rev Immunol. 2003 Dec;3(12):952-61. (PMID: 14647477)
Mol Cell Proteomics. 2020 Mar;19(3):432-443. (PMID: 31937595)
Cancer Res. 2018 Aug 15;78(16):4627-4641. (PMID: 29789417)
Mol Cell Proteomics. 2015 Mar;14(3):658-73. (PMID: 25576301)
Anal Bioanal Chem. 2019 Apr;411(11):2339-2349. (PMID: 30899997)
ACS Appl Mater Interfaces. 2020 Mar 4;12(9):10080-10095. (PMID: 32048822)
Semin Immunol. 2020 Feb;47:101387. (PMID: 31952902)
Proteomics. 2018 Jun;18(12):e1700284. (PMID: 29505699)
Nat Rev Drug Discov. 2019 Mar;18(3):197-218. (PMID: 30610226)
Oncoimmunology. 2018 May 7;7(8):e1457596. (PMID: 30221051)
Blood. 2015 Sep 3;126(10):1203-13. (PMID: 26138685)
J Immunol. 2017 Nov 1;199(9):3360-3368. (PMID: 28978689)
J Immunol. 2004 Mar 1;172(5):2944-52. (PMID: 14978097)
Proc Natl Acad Sci U S A. 2014 Mar 25;111(12):4507-12. (PMID: 24616531)
Nat Commun. 2016 Nov 21;7:13404. (PMID: 27869121)
Nat Rev Clin Oncol. 2021 Sep;18(9):591-602. (PMID: 33976418)
Sci Rep. 2019 Dec 6;9(1):18558. (PMID: 31811195)
Genome Med. 2016 Mar 30;8(1):33. (PMID: 27029192)
Nat Rev Cancer. 2019 Mar;19(3):133-150. (PMID: 30755690)

Keywords: HLA peptides; affinity purification; ligandome; microfluidics; thiol−enes

0 (Antigens, Neoplasm)
0 (Histocompatibility Antigens Class I)
0 (Ligands)
0 (Peptides)

Date Created: 20211004 Date Completed: 20211102 Latest Revision: 20211102

20231215

PMC8552492

10.1021/acsnano.1c04371

34605646